Next Article in Journal
The Wound-Healing Potential of Olea europaea L. Cv. Arbequina Leaves Extract: An Integrated In Vitro, In Silico, and In Vivo Investigation
Next Article in Special Issue
When Is the Right Moment to Pick Blueberries? Variation in Agronomic and Chemical Properties of Blueberry (Vaccinium corymbosum) Cultivars at Different Harvest Times
Previous Article in Journal
Identification of Medicinal Compounds of Fagopyri Dibotryis Rhizome from Different Origins and Its Varieties Using UPLC-MS/MS-Based Metabolomics
Previous Article in Special Issue
Poisonous Plants of the Indian Himalaya: An Overview
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Metabolites
Volume 12
Issue 9
10.3390/metabo12090792
metabolites-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Metabolic Profiling of Jasminum grandiflorum L. Flowers and Protective Role against Cisplatin-Induced Nephrotoxicity: Network Pharmacology and In Vivo Validation

by
Moneerah J. Alqahtani
1,
Sally A. Mostafa
2,
Ismail A. Hussein
3,
Seham Elhawary
4,
Fatma A. Mokhtar
5,
Sarah Albogami
6,
Michał Tomczyk
7,
Gaber El-Saber Batiha
8 and
Walaa A. Negm
9,*
1
Department of Pharmacognosy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia
2
Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Mansoura University, Mansoura 35511, Egypt
3
Department of Pharmacognosy and Medicinal Plants, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt
4
Department of Pharmacognosy, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt
5
Department of Pharmacognosy, Faculty of Pharmacy, ALSalam University, Al Gharbiya, Kafr El Zayat 31616, Egypt
6
Department of Biotechnology, College of Science, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia
7
Department of Pharmacognosy, Medical University of Białystok, ul. Mickiewicza 2a, 15-230 Białystok, Poland
8
Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour 22511, Egypt
9
Department of Pharmacognosy, Faculty of Pharmacy, Tanta University, Tanta 31527, Egypt
*
Author to whom correspondence should be addressed.
Metabolites 2022, 12(9), 792; https://doi.org/10.3390/metabo12090792
Submission received: 27 July 2022 / Revised: 15 August 2022 / Accepted: 22 August 2022 / Published: 25 August 2022
(This article belongs to the Special Issue Identification and Therapeutic Properties of Secondary Metabolites of Medicinal Plants)
Browse Figures
Versions Notes

Abstract

:
Cisplatin (CP) is a powerful chemotherapeutic agent; however, its therapeutic use is restricted due to its nephrotoxicity. In this work, we profiled the phytoconstituents of Jasminum grandiflorum flower extract (JGF) using LC-MS/MS and explored the possible molecular mechanisms against acute renal failure through pharmacological network analysis. Furthermore, the possible molecular mechanisms of JGF against acute renal failure were verified in an in vivo nephrotoxicity model caused by cisplatin. LC-MS analysis furnished 26 secondary metabolites. Altogether, there were 112 total hit targets for the identified metabolites, among which 55 were potential consensus targets related to nephrotoxicity based on the network pharmacology approach. Upon narrowing the scope to acute renal failure, using the DisGeNET database, only 30 potential targets were determined. The computational pathway analysis illustrated that JGF might inhibit renal failure through PI3K-Akt, MAPK signaling pathway, and EGFR tyrosine kinase inhibitor resistance. This study was confirmed by in vivo experiment in which kidneys were collected for histopathology and gene expression of mitogen-activated protein kinase 4 (MKK4), MKK7, I-CAM 1, IL-6, and TNF receptor-associated factor 2 (TRAF2). The animal-administered cisplatin exhibited a substantial rise in the expression levels of the MMK4, MKK7, I CAM 1, and TRFA2 genes compared to the control group. To summarize, J. grandiflorum could be a potential source for new reno-protective agents. Further experiments are needed to confirm the obtained activities and determine the therapeutic dose and time.

1. Introduction

Cisplatin is a powerful chemotherapeutic drug that can be used to cure tumors. However, CP has a number of side effects, including nephrotoxicity, which is linked to a high morbidity and mortality rate [1,2]. Nephrotoxicity is caused by cisplatin due to apoptosis and necrosis [3], and tubules inflammation [4]. The oxidative stress triggered by cisplatin leads to the development of renal tubule damage [5]. The formation of reactive oxygen and nitrogen species (ROS and RNS) alters the structure and function of cellular membranes. [6]. Consequently, their buildup in the kidneys and lysosomes [7] elucidated the mechanisms for CP-induced nephropathy [8]. Whereas many pathways for CP-induced nephrotoxicity have been investigated, including mitochondrial malfunction, inflammation, DNA damage, oxidative stress, and apoptosis, the ultimate process is still unknown [9,10].
Therefore, antioxidants and free radical scavengers can aid in the prevention of cisplatin-induced nephrotoxicity. Cisplatin causes apoptosis by disrupting DNA [11]. Many signaling pathways that can be activated by lipid peroxidation and oxidative stress affect cell survival or death in response to cisplatin [12]. Chemical and physical stressors stimulate the mitogen-activated protein kinase (MAPK) pathways, which modulate differentiation, proliferation, and death [13]. The three main MAPK pathways terminate in ERK, p38, and JNK/SAPK enzymes.
Cisplatin is also seen in numerous cell lines as renal epithelial cells, which stimulate these three pathways [14,15]. Inflammation, cell cycle regulation, and differentiation are all affected by p38 MAPK [16]. However, its significance in cancer treatment is unclear. Some researchers believe that p38 MAPK regulates the p53-mediated response to cisplatin [17,18,19,20].
Plants and their components are a better choice for treating ailments than any manufactured chemical [21]. The medicinal plant Jasminum grandiflorum Linn. (Family: Oleaceae) is widely utilized for both decorating and therapeutic value. J. grandiflorum flower (JGF) is traditionally used to treat mental illness, wounds, infections, skin injuries such as conjunctivitis and dermatitis, dysmenorrhea, spasms, ulcers, and cancer. In China, JGF is also extensively drunk as a heat-clearing and purifying beverage [22,23]. Several beneficial components, including flavonoids, iridoids, triterpenoids, secoiridoids, and lignans, have been identified from J. grandiflorum [24,25].
Although other Jasminum species and different organs have been investigated, the active metabolites of J. grandiflorum flowers (JGF) growing in Egypt have never been studied [26,27]. Here, we analyzed the bioactive compounds of JGF extract using high-performance liquid chromatography coupled with photodiode array detector/mass spectrometry (HPLC-PDA-MS/MS), and then used network pharmacology to explore the connections between the active constituents of JGF, possible protein targets, and hub-signaling pathways related to acute renal failure. Furthermore, in vivo studies investigating JGF’s antioxidant activity in cisplatin-induced renal damage treatment in rat models corroborated the molecular processes predicted by the network pharmacology method against acute renal failure.

2. Materials and Methods

2.1. JGF Extraction

Jasminum grandiflorum Linn. flower powder was made from dried fine crushed flowers collected from Keram fields in El-Behaira Governorate, Egypt. Dr. Mohammed El-Gebaly (Consultant in Orman Garden) verified the plant, and a voucher sample (# 3.10.16.6) was preserved at the Department of Pharmacognosy, Cairo University.
The powdered flower material (1 kg) was extracted with 80% aqueous methanol by percolation (3 × 3 L). The extract was concentrated under reduced pressure to afford a residue (108.8 g) of dry J. grandiflorum flower extract (JGF).

2.2. JGF Analysis

A Thermo Finnigan Surveyor Plus HPLC apparatus connected to a quaternary pump, a Surveyor UV–Vis photodiode array detector, and an LCQ-Duo ion trap mass spectrometer, via an electrospray ionization source, was utilized. The experiment was performed on a Gemini C18 110 Å (150 × 2 mm, 5 μm). A gradient of water and acetonitrile (ACN) (0.1% formic acid each) was applied from 5% to 30% ACN over 90 min, with a flow rate of 1 mL/min and a 1:1 split before the ESI source
The injection volume was 5 μL with 1 mL/min flow rate. For the negative ionization mode, the following were the ESI conditions: 350 °C, 35 psi nebulizer pressure, 10 L/min N2 drying gas flow rate, mass range 50–2000 m/z. The system was controlled with XcaliburTM 2.0.7 software. The negative ion mode operating parameters of the MS were employed [28].

2.3. Prediction of Bioactive Ingredients of JGF

All the compounds of JGF by LC/MS/MS analysis were considered as candidate compounds. As an online chemical database, PubChem Database (http://pubchem.ncbi.nlm.nih.gov/ accessed on 13 March 2022) was utilized to obtain the chemical data of identified compounds (3D molecular structures, PCIDs, conocial smiles). The 3D molecular structure files were uploaded to the Binding DB database (https://www.bindingdb.org/bind/index.jsp accessed on 20 March 2022), an online tool for identifying drug targets. We obtained anticipated drug targets for each metabolite using this web tool. We identified the target genes with a normalized fit score of >0.7 as prospective JGF targets after combining the duplicate data [29].

2.4. Potential Targets Intersection of JGF with Disease

Using the NCBI Gene database (https://www.ncbi.nlm.nih.gov/gene/ accessed on 22 March 2022) [30], and the Online UniProtKB/Swiss-Prot database (https://www.uniprot.org/help/uniprotkb accessed on 25 March 2022) [31], the genes associated with renal fibrosis were gathered from DisGeNet and NCBI databases [32]. The keywords used were “kidney disease”, “acute kidney insufficiency”, “chronic kidney disease”, “chronic kidney failure”, “kidney injury”, “kidney insufficiency”, “acute kidney failure”, kidney ischemia”, prerenal acute kidney”, and “glomerular filtration”. The targets were annotated human genes in this experiment. The interaction of the collected targets was then assigned as a possible therapeutic target. The STRING database was utilized to determine the interaction connection between target proteins.

2.5. Protein–Protein Interaction (PPI) Data

The PPI data were acquired from the STRING database (https://string-db.org/cgi/network?taskId=bIDN4htc9NBY&sessionId=bZWvNlZHMn9h accessed on 27 March 2022) [33], as a reliable database for predicting direct and indirect protein–protein interactions. The target proteins were chosen with the human species “Homo sapiens” and a confidence score greater than 0.4. STRING was used to find proteins that interacted with the indicated targets of JGF-isolated compounds directly or indirectly and acute renal failure [34].

2.6. Network Construction and Visualization

The Cytoscape network analysis program version 3.9.0 (a software platform that visualizes complex networks and integrates the results) was used to construct compound–target, protein–protein interaction (PPI), and compound–target–disease networks [35]. The difference was deemed significant at p < 0.05. Nodes represent targets, compounds, and renal diseases in the graphical network, while edges represent corresponding interactions.

2.7. Pathway and Functional Enrichment Analysis

The represented pathways related to JGF and acute renal failure were retrieved by the KEGG (Kyoto Encyclopedia of Genes) enrichment analyses (https://www.genome.jp/kegg accessed on 4 April 2022) [36] and Gene Ontology (ShinyGO) database (http://bioinformatics.sdstate.edu/go/ accessed on 7 April 2022) [37] to investigate the biological processes, cellular components, molecular functions, and involved pathways.

2.8. Animals

The experiment was performed under the guidelines of the Research Ethical Committee (Faculty of Pharmacy, Tanta University, Egypt, Approval #PO-21-00109). Male Sprague Dawley (230–260 g) rats were housed under standard conditions of temperature (22 ± 1 °C) and humidity (50–55%), and a 12-h light/dark cycle. There was plenty of food and drink.

2.9. In Vivo Experimental Design

The rats were divided into four groups (15 each) at random: the first group was given saline (2.5 mL/kg) intraperitoneally (IP) (normal control group); for the second group, a single dosage of 5 mg/kg CP (Pfizer Company) (1 mg/mL sterile concentrate) was given IP (CP group). For 14 days, the third group was given 40 mg/kg JGF dissolved in water orally (JGF group). The fourth group was given 40 mg/kg JGF dissolved in water orally for two weeks, with a single CP (5 mg/kg, i.p.) dosage on the tenth day. All rats were weighed and anesthetized before decapitation 24 h after the last treatment. Sera were separated after blood samples were collected. The kidneys were removed right away in an ice-cold saline solution. For histopathological and gene expression research, portions of kidneys were sliced into small pieces.

2.10. Estimation of Blood Urea Nitrogen and Serum Creatinine

Blood urea nitrogen (BUN) was monitored spectrophotometrically following Tabacco et al. [38]. In summary, serum was diluted 1:4 in normal saline, and 5 μL of diluted serum and standard was added to microplate wells, followed by 150 μL of urease mix solution. At room temperature, the plate was incubated for 15 min with shaking. Each well was then filled with 150 μL of alkaline hypochlorite. After 10 min at room temperature, using a microplate reader, the absorbance of each sample was measured in duplicate at 620 nm. A standard curve was prepared to calculate the concentration. Serum creatinine was detected following the procedures of Fabiny and Ertingshausen [39]. Briefly, after 30 s, picric acid (17.5 mmol/L final concentration)/NaOH solution (0.16 mol/L final concentration) was added to 100 μL of serum samples, and the standard and the absorbance of the standard and sample were measured after 2 min. The creatinine concentration was then estimated by dividing the sample’s delta absorbance by the control’s delta absorbance multiplied by the standard concentration.

2.11. Determination of Malondialdehyde (MDA) of Lipid Peroxidation

The concentration of MDA was determined in tissues using the method previously established by Satoh [40] and Ohkawa et al. [41], due to MDA being the primary product of membrane lipid peroxidation. The idea of this approach is based on the development of a pink color as a result of MDA and thiobarbituric acid reacting. The reaction yields a pink thiobarbituric acid reactive substance (TBARS) with a spectrophotometric wavelength of 532 nm.

2.12. Determination of Glutathione Levels (GSH) in Kidney Tissues

GSH concentration was measured using Beutler’s method [42]. The procedure is established by reducing 5,5' dithiobis (2—nitrobenzoic acid) with GSH to generate a yellow compound. The reduced chromogen’s absorbance could be determined at 405 nm and was directly proportional to GSH content.

2.13. RNA Extraction and Gene Expression Studies

TRIzol reagent (Invitrogen, Waltham, MA, USA) was used to purify the RNA. Thermo Scientific Maxima First Strand DNA Synthesis Kit with dsDNase was then used to make complementary DNA (Thermo Fisher Scientific, Rockford, IL, USA). The control gene was the B actin gene. Primer 3 PLUS software was used to create gene primer sets (v. 0.4.0; 163 https://frodo.wi.mit.edu/; accessed on 29 December 2021 Table S1). Real-time PCR assays were conducted using the Applied Biosystem 7500 real-time PCR detection system (Life Technologies, Carlsbad, CA, USA) with the SensiFAST SYBR Lo-ROX PCR Master Mix Kit (Bioline, Toronto, UK). The overall reaction volume was 20 μL, with the following thermal reaction profile: initial denaturation at 95 °C for 2 min followed by 40 cycles of 95 °C for 5 s, then 60 °C for 30 s. The method (2−ΔΔCt) was used for the calculation of fold induction values [43].

2.14. Histopathology Assessment

Each group’s kidneys were preserved in a 10% neutral buffered formaldehyde solution. The conventional process was followed for tissue dehydration, xylene cleaning, and paraffin embedding. Hematoxylin and eosin, as well as periodic acid schief (PAS), were used to stain sections cut using a rotary microtome at 5–7 μm thickness.

2.15. Statistical Analysis

All the tests were done in triplicate, and the data were reported using SPSS software version 26 as means and standard deviation (SD) (IBM Corp., Version 26.0. Armonk, NY, USA). ANOVA was used to compare the parameters obtained from the various tested groups. The statistical significance of the received data was assessed using p < 0.05.

3. Results

3.1. JGF Phytochemical Profile

A total of 26 secondary metabolites were tentatively identified in JGF using LC-MS/MS. The main compounds are divided into several subclasses, including secoiridoids, flavonoids, and phenolic and organic acids. Comprehensive profiling is presented in Table 1, and the total ion chromatogram (TIC) of JGF is displayed in Supplementary Figure S1.

3.2. Compound–Target Network Construction

A total of 112 targets were found among the 26 identified chemicals in the NCBI Gene and UniProtKB/Swiss-Prot databases. A total of 55 potential renal disease targets were identified from the DisGeNet database, among which only 30 targets are related to acute renal failure. Taking the intersection of the 112 potential targets and the compounds in JGF into account, we constructed a compound–target network using Cytoscape (Figure 1 and Table S2), which included 138 nodes (26 for potential phytoconstituents and 112 for protein targets) with 547 edges. The top hit targets for the identified compounds were PTPN1, NOX4, and TNF, with no edges > 10.
The 112 possible therapeutic target genes were loaded into the STRING database, which supplied predicted interaction data, and then imported into Cytoscape 3.9.0 for analysis and network construction (Figure 2). In the PPI network, the top 17 genes, prioritized by interactions, were gathered to be the hub targets, each represented by edges > 25, namely HSP90AA1, TNF, ESR1, VEGFA, EGFR, PPARG, PTGS2, HSP90AB1, CA4, MMP9, AR, KDR, CYP3A4, HDAC1, APP, CDK1, and CDK2. These genes contributed to the gene–disease interactions. The PPI was represented in 4 clusters, with 131 nodes, 831 edges, and an average local clustering coefficient equal to 0.532.

3.3. Potential Targets Intersection of JGF with Disease

The DisGeNET online database was used to interpret the associated diseases with the identified 112 target hits of the JGF-identified compounds. Upon filtration of the results to narrow the scope to urogenital disorders, a total of 47 genes were obtained (Figure 3). To direct the research scope to acute renal failure disorders, 30 genes were detected (Figure 4).

3.4. Compounds–Common Targets–Renal Failure Pharmacology Network

The combination and merging of the JGF–compounds, compounds–targets, and targets–non-cancer renal diseases networks formed the complete pharmacology network that correlates the identified compounds from JGF, as described in Figure 5.

3.5. Target Genes–Pathways Network

To investigate the probable pathways of JGF on kidney disorders, the pathway enrichment of 112 probable targets was targeted by 26 identified compounds interacting with renal diseases using the KEGG and ShinyGO databases. The pathways analysis conducted with the KEGG diagram illustrated the top 24 pathways annotated by the target genes. Upon focusing on the pathways involved in acute renal failure disorders, three signaling pathways were identified: PI3K-Akt, MAPK, and EGFR tyrosine kinase inhibitor resistance. Each pathway diagram is illustrated to elaborate the specific genes among our targets involved directly in the nominated pathways as described by the KEGG labeled diagrams (Figure 6 and Table S3).

3.6. GO Enrichment Analysis

Using GO terms, the gene ontology results are illustrated as networks (Figure 7), representing the analysis of the cellular components and illustrating the role of the target hits of JGF phytometabolites. The major identified cellular components according to fold enrichment are receptor complex (GO:0043235), apical part of cell (GO:0045177), and perinuclear region of cytoplasm (GO:0048471) (Table S4). The molecular functions enriched to all targets were arranged according to fold enrichment, and the top molecular functions are protein kinase activity (GO:0004672), phosphotransferase activity, alcohol group as acceptor (GO:0016773), and oxidoreductase activity (GO:0016491) (Table S5). The biological processes enriched for all the target hits of JGF were arranged according to fold enrichment, and the top biological processes are olefinic compound metabolic process (GO:0120254), cellular response to oxygen-containing compound (GO:1901701), and response to oxygen-containing compound (GO:1901700) (Table S6).

3.7. In Vivo Studies

3.7.1. Effects of JGF on Bodyweight, BUN, and Serum Creatinine

The impact of CP, JGF, and their combination on rat body weight is shown in Figure 8. Compared to the control group, CP-treated animals lost weight significantly (p < 0.05) at the end of the experiment. Interestingly, JGF treatment alone increased the body weight compared to the control and cisplatin groups. In addition, treatment of JGF in combination with CP attenuated the deleterious effects of CP and increased the declined body weight (p < 0.05, Figure 8).
Cisplatin elevated BUN and serum creatinine levels substantially compared to the control group (p < 0.001). However, JGF combined with CP completely reversed the elevated levels, which returned to normal levels in the control group (Figure 8). Of note, there were no substantial differences in BUN and serum creatinine in the JGF group compared to the control group.

3.7.2. Effects of JGF on Renal Oxidative Stress

CP elevated MDA and lowered GSH levels in renal tissue substantially compared to the control group. Remarkably, pretreatments with JGF inverted the adverse effects and returned them to normal levels, much like in the control group (Figure 9). Compared to the control group, treatment of JGF alone did not affect MDA or GSH levels.

3.7.3. Effects of JGF on the Levels of Gene Expression

Figure 10 depicts the effects of CP, JGF, and their combination on MKK4, MKK7, I-CAM-1, IL-6, and TRAF 2 expression levels in kidney tissues. CP alone resulted in a remarkable rise in tested markers (p < 0.001) compared to the control group. Pretreatments with JGF inverted the elevated levels, leading to a complete setback to normal values (Figure 10). In the JGF group, no significant alterations in any of the tested markers were observed.

3.7.4. Histopathology

Figure 11 depicts the impact of CP and JGF on histological alterations in renal tissues. Under a light microscope, the kidney tissues from the normal and treated rat groups were examined. The kidneys of control rats showed no glomeruli histological abnormalities, proximal convoluted tubules, or distal convoluted tubules. The section in the cortex of rats that received cisplatin showed severe effects on the renal tubules, with signs of tubular cell lining vacuolation and intratubular cast deposition. The section in the cortex of rats that received JGF showed normal architecture. The section in the cortex of rats that received cisplatin + JGF showed almost normal renal glomeruli and tubules, apart from minimal tubular cell lining vacuolations.

4. Discussion

CP is an anticancer medicine that was established to treat a variety of malignancies, including testicular, head, neck, ovary, lung, and breast cancers [1]. However, its dose-limiting adverse effect is nephrotoxicity [44]. Acute renal damage was also detected in roughly 20–30% of patients taking CP [45], and hypomagnesemia in approximately 40–100% of patients [46], as well as distal renal tubular acidosis, hypocalcemia, renal salt wasting, hyperuricemia, and Fanconi-like syndrome [47].
Nephrotoxicity is defined as a decrease in renal function that results in an elevation in serum creatinine and blood urea levels as a result of CP [48]. Serum creatinine and BUN levels were considerably higher in CP-treated rats compared to the untreated group in this study, indicating that CP caused nephrotoxicity as indicated by a reduction in glomerular filtration rate. JGF significantly reduced the increased serum creatinine and BUN levels caused by CP, restoring them to normal values in the control group.
Other research suggests that CP causes ROS and an immunological response, both of which are nephrotoxic mediators [49,50]. MDA and GSH were assessed as indicators for oxidative stress in this investigation. The action of cisplatin on renal tissue resulted in a considerable rise in MDA and a reduction in GSH. The administration of JGF, on the other hand, resulted in considerable reductions in lipid peroxidation and stimulated a rise in GSH content in the kidney. As a result of the improved oxidant status, JGF can protect the kidney from damage caused by cisplatin. JGF may furnish its nephroprotective activity through its antioxidant properties.
The p38-MAPK stress pathway, activated by inflammatory cytokines such as TNF-α or IL-1, is a critical regulator of cell apoptosis [51]. After cisplatin injury, the amount of inflammatory cytokines and chemokines is raised in the kidney [52]. CP boosted the expression of inflammatory cytokines such as IL-6 in the current study. TNF-α, IL-1β, macrophage inflammatory protein-2 (MIP-2), monocyte chemoattractant protein-1 (MCP-1), ICAM-1, and TGF-β were all upregulated in the kidneys of CP-treated animals [53]. JGF administration enhanced the CP-induced rise in IL-6 expression levels.
Due to the highly complex biochemistry of plants, which includes a variety of semi-polar molecules, including important secondary metabolite groups, which may be best separated and detected by LC-MS techniques, LC-MS-based approaches are anticipated to be particularly significant for plants. Mass spectrometry is a reliable detection method, and using tandem mass spectrometry can improve selectivity and specificity. The analysis of several phytochemicals can be conducted using LC-MS since it is sensitive and selective [54].
The negative ionization modes of LC-MS/MS analysis of J. grandiflorum flower extract resulted in the detection of twenty-six bioactive metabolites compounds. The identified metabolites belong to several phytochemical classes, such as secoiridoids, phenolic acids, and flavonoids, in agreement with the previous literature [27,55].
HPLC–PDA–MS profiling of JGF produces extremely rich metabolite profiles. LC/MS analysis of JGF demonstrated that it has significant flavonoids and polyphenolic content. The different flavonoid subclasses (flavone, flavanone, and flavonols) were also represented by aglycones and glycosides.
Flavonoids are essential in a wide range of nutraceutical, pharmacological, medical, and cosmetic uses because they are linked to a wide range of health-promoting effects [56]. This is because they possess strong anti-oxidative, anti-inflammatory, anti-mutagenic, antimicrobial, anti-carcinogenic, vascular, and other therapeutic properties, as well as the ability to modify crucial cellular enzyme processes [57]. The present study agreed with previous reports that demonstrate the protective effect of natural products containing flavonoids as antioxidants and anti-inflammatory agents in kidney injury [58,59,60].
Cisplatin-induced inflammatory cytokines primarily rely on forming reactive oxygen species (ROS), NFκB activation, and p38 MAPK activation. TNF-α and IL-1 substantially activate the stress-activated group of MAPKs (JNK and p38) [52]. This was supported by the current study, which found that a single dose of CP increased JNK and P38 expression. TNF activates JNK through the TNF receptor-associated factor (TRAF) class of adaptor proteins [61].
The present study suggests that cisplatin induced TRAF2 overexpression is the cause of nephrotoxicity and apoptosis. The reduction in TRAF2 expression in kidney tissues after JGF administration in CP-treated rats implies that JGF may safeguard against nephrotoxicity caused by CP through regulating apoptotic pathways. The TRAF2 adapter protein is recruited when TNF receptors are activated [62,63]. TRAF2 expression needs to be activated for TNF to activate JNK [62].
According to a previous study, JNK genes have an essential role in modifying the pro- and anti-apoptotic proteins in the mitochondria in the nephrotoxicity caused by chemotherapy [64]. By blocking anti-apoptotic proteins, JNK with ROS can increase apoptosis [65]. JNK can also be activated by MKK4 and MKK7 phosphorylation at threonine and tyrosine. MAPKKK phosphorylates two locations in the T-loop to activate MKK4 and MKK7 protein kinases [66].
The MKK7 is mainly triggered by cytokines, whereas MKK4 is activated primarily by environmental stress [67]. In the present work, CP-induced changes in MKK4 and MKK7 expression were reduced in CP-treated rats by supplementing them with JGF. MKK3, MKK4, and MKK6 all activate P38 MAPK [68]. After a single cisplatin dosage, P38 expression was increased in this investigation. Inhibition of p38 MAPK, ERK, or JNK with particular pharmacologic or genetic inhibitors decreased inflammation and kidney injury in multiple investigations. In CP-treated rats, JGF treatment restored P38 expression and decreased apoptosis.
JGF showed a significant nephroprotective effect in rats, and its nephroprotection mechanism could be attributable to the presence of a variety of phytochemicals, including secoiridoids, flavonoids, and phenolic and organic acids with antioxidant properties and free-radical-scavenging properties. Therefore, this plant could be useful in treating renal failure caused by nephrotoxic drugs.

5. Conclusions

The metabolites in J. grandiflorum were detected using HPLC-PDA-MS/MS, including quercetin, myricetin, kaempferol, isorhamnetin flavonoids, and other secoiridoid derivatives. Our findings could contribute to the understanding of the molecular mechanisms of JGF in CP nephrotoxicity, which were confirmed by in vivo research that supported the molecular processes predicted by the network pharmacology method. Compared to the control group, a single dose of CP to rats caused nephrotoxicity, which was related to a considerable rise in BUN and serum creatinine and a significant increase in MDA in renal tissues. The expression levels of the MMK4, MKK7, I CAM 1, and TRFA2 genes were considerably higher in the cisplatin-treated animals than in the control. Furthermore, the histological investigation revealed that cisplatin induced significant tubular cell lining vacuolation and intratubular cast deposition in the renal tubules. JFG treatment reduced cisplatin-induced gene expression changes and kidney structural and functional abnormalities. Gene expression data were also corroborated by histological investigation of kidney tissues. Our study suggests that the anti-inflammatory effects of JGF can protect from CP-induced nephrotoxicity through lowering oxidative stress and repairing the histopathological changes against cisplatin use. However, further studies should be carried out in the future to reveal the clinical effectiveness of J. grandiflorum as a renal protective drug in preclinical and clinical trials.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/metabo12090792/s1, Figure S1. The total ion chromatogram (TIC) of J. grandiflorum flower extract (JGF), Table S1. Sequence genes, Table S2. Network analysis of the identified compounds arranged in descending order according to the degree of centrality, Table S3. Top KEGG pathways to the identified target genes corresponding to the identified compounds of Jasminum grandiflorum flowers, number of genes involved in each pathway > 3 genes, Table S4. Top cellular components enriched to the target genes identified as targets to identified compounds from JGF, Table S5. Top Molecular functions enriched to the target genes identified as targets of identified compounds from JGF, Table S6. Top biological process enriched to the target genes identified as targets of identified compounds from JGF.

Author Contributions

Conceptualization, F.A.M. and W.A.N.; data curation, M.J.A. and S.E.; formal analysis, S.A.; investigation, M.J.A., S.A.M., I.A.H., F.A.M. and W.A.N.; methodology, S.A.M. and F.A.M.; project administration, G.E.-S.B. and W.A.N.; resources, M.J.A., I.A.H., S.A. and G.E.-S.B.; software, F.A.M.; supervision, S.E. and M.T.; validation, M.T. and G.E.-S.B.; writing—original draft, S.A.M., I.A.H., F.A.M. and W.A.N.; writing—review and editing, S.E., M.T. and W.A.N. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The experiment was performed under the guidelines of the Research Ethical Committee (Faculty of Pharmacy, Tanta University, Egypt, Approval #PO-21-00109).

Informed Consent Statement

Not applicable.

Data Availability Statement

Data is contained within the article and supplementary material.

Acknowledgments

We would like to acknowledge Taif University Researchers Supporting Project (number TURSP-2020/202), Taif University, Taif, Saudi Arabia.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

PTPN1Receptor-interacting serine/threonine-protein kinase 1
NOX4NADPH oxidase 4
TNFTumor necrosis factor
p38 MAPKMitogen-activated protein kinase signaling pathway
HSP90AA1Heat shock protein HSP 90-alpha
ESR1Estrogen receptor
VEGFAVascular endothelial growth factor A
EGFREpidermal growth factor receptor
PPARGPeroxisome proliferator-activated receptor gamma
PTGS2Cyclooxygenase
HSP90AB1Heat shock protein HSP 90-beta
CA4Carbonic anhydrase 4
MMP9Matrix metalloproteinase 9
ARAndrogen Receptor
CYP3A4Cytochrome P450 3A4
HDAC1Histone deacetylase
APPbeta-Glucuronidase (β-glucuronidase)
CDK1Cyclin-dependent kinase 1
CDK2Cyclin-dependent kinase 2
KDRVascular endothelial growth factor receptor 2
ERKExtracellular signal-regulated kinases
JNKc-Jun N-terminal protein kinases (JNK), also known as stress-activated protein kinases
STRINGThe STRING database is one of several online resources dedicated to organism-wide protein association networks
DisGeNETA discovery platform containing one of the largest publicly available collections of genes and variants associated with human diseases
HDAC1Histone deacetylase
GOGene ontology
JGFJasminum grandiflorum flowers
HPLC-PDA/MSHigh-performance liquid chromatographic coupled with diode array detector/mass spectrometry

References

  1. Najafi, M.; Tavakol, S.; Zarrabi, A.; Ashrafizadeh, M. Dual role of quercetin in enhancing the efficacy of cisplatin in chemotherapy and protection against its side effects: A review. Arch. Physiol. Biochem. 2020, 10, 1–15. [Google Scholar] [CrossRef] [PubMed]
  2. Alotaibi, B.; El-Masry, T.A.; Elekhnawy, E.; El-Kadem, A.H.; Saleh, A.; Negm, W.A.; Abdelkader, D.H. Aqueous core epigallocatechin gallate PLGA nanocapsules: Characterization, antibacterial activity against uropathogens, and in vivo reno-protective effect in cisplatin induced nephrotoxicity. Drug Deliv. 2022, 29, 1848–1862. [Google Scholar] [CrossRef] [PubMed]
  3. Zhu, X.; Jiang, X.; Li, A.; Zhao, Z.; Li, S. S-Allylmercaptocysteine attenuates cisplatin-induced nephrotoxicity through suppression of apoptosis, oxidative stress, and inflammation. Nutrients 2017, 9, 166. [Google Scholar] [CrossRef] [PubMed]
  4. Kumar, P.; Sulakhiya, K.; Barua, C.C.; Mundhe, N. TNF-α, IL-6 and IL-10 expressions, responsible for disparity in action of curcumin against cisplatin-induced nephrotoxicity in rats. Mol. Cell. Biochem. 2017, 431, 113–122. [Google Scholar] [CrossRef] [PubMed]
  5. Oh, C.J.; Ha, C.-M.; Choi, Y.-K.; Park, S.; Choe, M.S.; Jeoung, N.H.; Huh, Y.H.; Kim, H.-J.; Kweon, H.-S.; Lee, J.-m. Pyruvate dehydrogenase kinase 4 deficiency attenuates cisplatin-induced acute kidney injury. Kidney Int. 2017, 91, 880–895. [Google Scholar] [CrossRef]
  6. Divya, M.K.; Lincy, L.; Raghavamenon, A.C.; Babu, T.D. Ameliorative effect of Apodytes dimidiata on cisplatin-induced nephrotoxicity in Wistar rats. Pharm. Biol. 2016, 54, 2149–2157. [Google Scholar] [CrossRef]
  7. Romero, F.; Pérez, M.; Chávez, M.; Parra, G.; Durante, P. Effect of uric acid on gentamicin-induced nephrotoxicity in rats–role of matrix metalloproteinases 2 and 9. Basic Clin. Pharmacol. Toxicol. 2009, 105, 416–424. [Google Scholar] [CrossRef]
  8. Pedraza-Chaverrí, J.; Barrera, D.; Maldonado, P.D.; Chirino, Y.I.; Macías-Ruvalcaba, N.A.; Medina-Campos, O.N.; Castro, L.; Salcedo, M.I.; Hernández-Pando, R. S-allylmercaptocysteine scavenges hydroxyl radical and singlet oxygen in vitro and attenuates gentamicin-induced oxidative and nitrosative stress and renal damage in vivo. BMC Clin. Pharmacol. 2004, 4, 5. [Google Scholar] [CrossRef]
  9. Malik, S.; Suchal, K.; Bhatia, J.; Khan, S.I.; Vasisth, S.; Tomar, A.; Goyal, S.; Kumar, R.; Arya, D.S.; Ojha, S.K. Therapeutic potential and molecular mechanisms of Emblica officinalis Gaertn in countering Nephrotoxicity in rats induced by the chemotherapeutic agent Cisplatin. Front. Pharmacol. 2016, 7, 350. [Google Scholar] [CrossRef]
  10. Dasari, S.; Tchounwou, P.B. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur. J. Pharmacol. 2014, 740, 364–378. [Google Scholar] [CrossRef] [Green Version]
  11. Pabla, N.; Dong, Z. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int. 2008, 73, 994–1007. [Google Scholar] [CrossRef] [PubMed]
  12. Abdel-Daim, M.M.; El-Sayed, Y.S.; Eldaim, M.A.; Ibrahim, A. Nephroprotective efficacy of ceftriaxone against cisplatin-induced subchronic renal fibrosis in rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 2017, 390, 301–309. [Google Scholar] [CrossRef] [PubMed]
  13. Ma, X.; Dang, C.; Kang, H.; Dai, Z.; Lin, S.; Guan, H.; Liu, X.; Wang, X.; Hui, W. Saikosaponin-D reduces cisplatin-induced nephrotoxicity by repressing ROS-mediated activation of MAPK and NF-κB signalling pathways. Int. Immunopharmacol. 2015, 28, 399–408. [Google Scholar] [CrossRef] [PubMed]
  14. Arany, I.; Megyesi, J.K.; Kaneto, H.; Price, P.M.; Safirstein, R.L. Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. Am. J. Physiol. Ren. Physiol. 2004, 287, F543–F549. [Google Scholar] [CrossRef]
  15. Negm, W.A.; El-Kadem, A.H.; Hussein, I.A.; Alqahtani, M.J. The Mechanistic Perspective of Bilobetin Protective Effects against Cisplatin-Induced Testicular Toxicity: Role of Nrf-2/Keap-1 Signaling, Inflammation and Apoptosis. Biomedicines 2022, 10, 1134. [Google Scholar] [CrossRef]
  16. Koul, H.K.; Pal, M.; Koul, S. Role of p38 MAP kinase signal transduction in solid tumors. Genes Cancer 2013, 4, 342–359. [Google Scholar] [CrossRef]
  17. Malik, S.; Suchal, K.; Gamad, N.; Dinda, A.K.; Arya, D.S.; Bhatia, J. Telmisartan ameliorates cisplatin-induced nephrotoxicity by inhibiting MAPK mediated inflammation and apoptosis. Eur. J. Pharmacol. 2015, 748, 54–60. [Google Scholar] [CrossRef]
  18. Bragado, P.; Armesilla, A.; Silva, A.; Porras, A. Apoptosis by cisplatin requires p53 mediated p38α MAPK activation through ROS generation. Apoptosis 2007, 12, 1733–1742. [Google Scholar] [CrossRef]
  19. Tsuchida, M.; Yokosawa, T.; Noguchi, T.; Shimada, T.; Yamada, M.; Sekiguchi, Y.; Hirata, Y.; Matsuzawa, A. Pro-apoptotic functions of TRAF2 in p53-mediated apoptosis induced by cisplatin. J. Toxicol. Sci. 2020, 45, 219–226. [Google Scholar] [CrossRef]
  20. Huang, J.-Y.; Lin, Y.-C.; Chen, H.-M.; Lin, J.-T.; Kao, S.-H. Adenine Combined with Cisplatin Promotes Anticancer Activity against Hepatocellular Cancer Cells through AMPK-Mediated p53/p21 and p38 MAPK Cascades. Pharmaceuticals 2022, 15, 795. [Google Scholar] [CrossRef]
  21. Negm, W.A.; Abo El-Seoud, K.A.; Kabbash, A.; Kassab, A.A.; El-Aasr, M. Hepatoprotective, cytotoxic, antimicrobial and antioxidant activities of Dioon spinulosum leaves Dyer Ex Eichler and its isolated secondary metabolites. Nat. Prod. Res. 2020, 35, 5166–5176. [Google Scholar] [CrossRef]
  22. Arun, M.; Satish, S.; Anima, P. Phytopharmacological profile of Jasminum grandiflorum Linn. (Oleaceae). Chin. J. Integr. Med. 2016, 22, 311–320. [Google Scholar] [CrossRef] [PubMed]
  23. Zhang, Y.; Sun, L.; Lai, X.; Peng, X.; Wen, S.; Zhang, Z.; Xie, Y.; Li, Q.; Chen, R.; Zheng, X. Gastroprotective effects of extract of Jasminum grandiflorum L. flower in HCl/EtOH-induced gastric mucosal ulceration mice. Biomed. Pharmacother. 2021, 144, 112268. [Google Scholar] [CrossRef] [PubMed]
  24. Tharakan, S.T. Phytochemical and pharmacological properties of five different species of Jasminum. Plant Arch. 2021, 21, 126–136. [Google Scholar]
  25. Elhawary, S.; Hala, E.-H.; Mokhtar, F.A.; Mansour Sobeh, E.M.; Osman, S.; El-Raey, M. Green synthesis of silver nanoparticles using extract of Jasminum officinal L. leaves and evaluation of cytotoxic activity towards bladder (5637) and breast cancer (MCF-7) cell lines. Int. J. Nanomed. 2020, 15, 9771. [Google Scholar] [CrossRef]
  26. El-Hawary, S.S.; El-Hefnawy, H.M.; Elemeery, M.N.; Osman, S.M.; El-Raey, M.A.; Mokhtar, F.A.; Pan, C.H.; Ibrahim, H.A. The role of active metabolites isolated from Jasminum multiflorum flowers against hepatitis C virus infection and related hepatocellular carcinoma. Nat. Prod. Res. 2022, 36, 2625–2629. [Google Scholar] [CrossRef]
  27. El-Hawary, S.S.; El-Hefnawy, H.M.; El-Raey, M.A.; Mokhtar, F.A.; Osman, S.M. Jasminum azoricum L. leaves: HPLC-PDA/MS/MS profiling and in-vitro cytotoxicity supported by molecular docking. Nat. Prod. Res. 2021, 35, 5518–5520. [Google Scholar] [CrossRef]
  28. Elmongy, E.I.; Negm, W.A.; Elekhnawy, E.; El-Masry, T.A.; Attallah, N.G.; Altwaijry, N.; Batiha, G.E.-S.; El-Sherbeni, S.A. Antidiarrheal and Antibacterial Activities of Monterey Cypress Phytochemicals: In Vivo and In Vitro Approach. Molecules 2022, 27, 346. [Google Scholar] [CrossRef]
  29. Doncheva, N.T.; Morris, J.H.; Gorodkin, J.; Jensen, L.J. Cytoscape StringApp: Network analysis and visualization of proteomics data. J. Proteome Res. 2018, 18, 623–632. [Google Scholar] [CrossRef]
  30. Brown, G.R.; Hem, V.; Katz, K.S.; Ovetsky, M.; Wallin, C.; Ermolaeva, O.; Tolstoy, I.; Tatusova, T.; Pruitt, K.D.; Maglott, D.R. Gene: A gene-centered information resource at NCBI. Nucleic Acids Res. 2015, 43, D36–D42. [Google Scholar] [CrossRef]
  31. Liu, T.; Lin, Y.; Wen, X.; Jorissen, R.N.; Gilson, M.K. BindingDB: A web-accessible database of experimentally determined protein–ligand binding affinities. Nucleic Acids Res. 2007, 35 (Suppl. S1), D198–D201. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Piñero, J.; Ramírez-Anguita, J.M.; Saüch-Pitarch, J.; Ronzano, F.; Centeno, E.; Sanz, F.; Furlong, L.I. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res. 2020, 48, D845–D855. [Google Scholar] [CrossRef] [PubMed]
  33. Szklarczyk, D.; Gable, A.L.; Nastou, K.C.; Lyon, D.; Kirsch, R.; Pyysalo, S.; Doncheva, N.T.; Legeay, M.; Fang, T.; Bork, P. The STRING database in 2021: Customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2021, 49, D605–D612. [Google Scholar] [CrossRef] [PubMed]
  34. Ahmed, S.R.; Al-Sanea, M.M.; Mostafa, E.M.; Qasim, S.; Abelyan, N.; Mokhtar, F.A. A Network Pharmacology Analysis of Cytotoxic Triterpenes Isolated from Euphorbia abyssinica Latex Supported by Drug-likeness and ADMET Studies. ACS Omega 2022, 7, 17713–17722. [Google Scholar] [CrossRef]
  35. Franz, M.; Lopes, C.T.; Huck, G.; Dong, Y.; Sumer, O.; Bader, G.D. Cytoscape. js: A graph theory library for visualisation and analysis. Bioinformatics 2016, 32, 309–311. [Google Scholar]
  36. Du, J.; Li, M.; Yuan, Z.; Guo, M.; Song, J.; Xie, X.; Chen, Y. A decision analysis model for KEGG pathway analysis. BMC Bioinform. 2016, 17, 407. [Google Scholar] [CrossRef]
  37. Ge, S.X.; Jung, D.; Yao, R. ShinyGO: A graphical gene-set enrichment tool for animals and plants. Bioinformatics 2020, 36, 2628–2629. [Google Scholar] [CrossRef]
  38. Tabacco, A.; Meiattini, F.; Moda, E.; Tarli, P. Simplified enzymic/colorimetric serum urea nitrogen determination. Clin. Chem. 1979, 25, 336–337. [Google Scholar] [CrossRef]
  39. Fabiny, D.L.; Ertingshausen, G. Automated reaction-rate method for determination of serum creatinine with the CentrifiChem. Clin. Chem. 1971, 17, 696–700. [Google Scholar] [CrossRef]
  40. Kei, S. Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clin. Chim. Acta 1978, 90, 37–43. [Google Scholar] [CrossRef]
  41. Ohkawa, H.; Ohishi, N.; Yagi, K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979, 95, 351–358. [Google Scholar] [CrossRef]
  42. Beutler, E. Improved method for the determination of blood glutathione. J. Lab. Clin. Med. 1963, 61, 882–888. [Google Scholar] [PubMed]
  43. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods 2001, 25, 402–408. [Google Scholar] [CrossRef] [PubMed]
  44. Sastry, J.; Kellie, S.J. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatric Hematol. Oncol. 2005, 22, 441–445. [Google Scholar] [CrossRef]
  45. Yang, S.-k.; Han, Y.-c.; He, J.-r.; Yang, M.; Zhang, W.; Zhan, M.; Li, A.-m.; Li, L.; Liu, Y.-t.; Wu, X.-q. Mitochondria targeted peptide SS-31 prevent on cisplatin-induced acute kidney injury via regulating mitochondrial ROS-NLRP3 pathway. Biomed. Pharmacother. 2020, 130, 110521. [Google Scholar] [CrossRef]
  46. Money, M.E.; Hamroun, A.; Shu, Y.; Matthews, C.; Ahmed Eltayeb, S.; Ciarimboli, G.; Metz, C.N. Case Report and Supporting Documentation: Acute Kidney Injury Manifested as Oliguria Is Reduced by Intravenous Magnesium Before Cisplatin. Front. Oncol. 2021, 11, 287. [Google Scholar] [CrossRef] [PubMed]
  47. Ruggiero, A.; Trombatore, G.; Triarico, S.; Capozza, M.A.; Coccia, P.; Attina, G.; Mastrangelo, S.; Maurizi, P. Cisplatin Toxicity in Children with Malignancy. Biomed. Pharmacol. J. 2019, 12, 1603–1612. [Google Scholar] [CrossRef]
  48. Farooqui, Z.; Ahmed, F.; Rizwan, S.; Shahid, F.; Khan, A.A.; Khan, F. Protective effect of Nigella sativa oil on cisplatin induced nephrotoxicity and oxidative damage in rat kidney. Biomed. Pharmacother. 2017, 85, 7–15. [Google Scholar] [CrossRef]
  49. Sharma, S.; Joshi, A.; Hemalatha, S. Protective effect of Withania coagulans fruit extract on cisplatin-induced nephrotoxicity in rats. Pharmacogn. Res. 2017, 9, 354. [Google Scholar]
  50. Rashed, L.A.; Hashem, R.M.; Soliman, H.M. Oxytocin inhibits NADPH oxidase and P38 MAPK in cisplatin-induced nephrotoxicity. Biomed. Pharmacother. 2011, 65, 474–480. [Google Scholar] [CrossRef]
  51. Suchal, K.; Malik, S.; Khan, S.I.; Malhotra, R.K.; Goyal, S.N.; Bhatia, J.; Kumari, S.; Ojha, S.; Arya, D.S. Protective effect of mangiferin on myocardial ischemia-reperfusion injury in streptozotocin-induced diabetic rats: Role of AGE-RAGE/MAPK pathways. Sci. Rep. 2017, 7, 42027. [Google Scholar] [CrossRef] [PubMed]
  52. Chowdhury, S.; Sinha, K.; Banerjee, S.; Sil, P.C. Taurine protects cisplatin induced cardiotoxicity by modulating inflammatory and endoplasmic reticulum stress responses. Biofactors 2016, 42, 647–664. [Google Scholar] [CrossRef] [PubMed]
  53. Bharara, A.; Grossman, C.; Grinnan, D.; Syed, A.; Fisher, B.; DeWilde, C.; Natarajan, R. Intravenous vitamin C administered as adjunctive therapy for recurrent acute respiratory distress syndrome. Case Rep. Crit. Care 2016, 2016, 8560871. [Google Scholar] [CrossRef] [Green Version]
  54. Alotaibi, B.; Mokhtar, F.A.; El-Masry, T.A.; Elekhnawy, E.; Mostafa, S.A.; Abdelkader, D.H.; Elharty, M.E.; Saleh, A.; Negm, W.A. Antimicrobial Activity of Brassica rapa L. Flowers Extract on Gastrointestinal Tract Infections and Antiulcer Potential Against Indomethacin-Induced Gastric Ulcer in Rats Supported by Metabolomics Profiling. J. Inflamm. Res. 2021, 14, 7411. [Google Scholar] [CrossRef] [PubMed]
  55. El Hawary, S.; El Sayed, A.; Helmy, M.W.; El Naggar, E.M.b.; Marzouk, H.S.; Bassam, S.M. DNA fingerprinting, biological and chemical investigation of certain Yucca species. Nat. Prod. Res. 2018, 32, 2617–2620. [Google Scholar] [CrossRef] [PubMed]
  56. Tsivelika, N.; Irakli, M.; Mavromatis, A.; Chatzopoulou, P.; Karioti, A. Phenolic Profile by HPLC-PDA-MS of Greek Chamomile Populations and Commercial Varieties and Their Antioxidant Activity. Foods 2021, 10, 2345. [Google Scholar] [CrossRef]
  57. Baskar, V.; Venkatesh, R.; Ramalingam, S. Flavonoids (antioxidants systems) in higher plants and their response to stresses. In Antioxidants and Antioxidant Enzymes in Higher Plants; Springer: Cham, Switzerland, 2018; pp. 253–268. [Google Scholar]
  58. Ridzuan, N.R.; Rashid, N.A.; Othman, F.; Budin, S.B.; Hussan, F.; Teoh, S.L. Protective role of natural products in cisplatin-induced nephrotoxicity. Mini Rev. Med. Chem. 2019, 19, 1134–1143. [Google Scholar] [CrossRef] [PubMed]
  59. Fang, C.-y.; Lou, D.-y.; Zhou, L.-q.; Wang, J.-c.; Yang, B.; He, Q.-j.; Wang, J.-j.; Weng, Q.-j. Natural products: Potential treatments for cisplatin-induced nephrotoxicity. Acta Pharmacol. Sin. 2021, 42, 1951–1969. [Google Scholar] [CrossRef]
  60. Negm, W.A.; Ibrahim, A.E.-R.S.; El-Seoud, K.A.; Attia, G.I.; Ragab, A.E. A new cytotoxic and antioxidant Amentoflavone Monoglucoside from Cycas revoluta Thunb growing in Egypt. J. Pharm. Sci. Res. 2016, 8, 343. [Google Scholar]
  61. Oladejo, A.O.; Li, Y.; Imam, B.H.; Ma, X.; Shen, W.; Wu, X.; Jiang, W.; Yang, J.; Lv, Y.; Ding, X. MicroRNA miR-24-3p Mediates the Negative Regulation of Lipopolysaccharide-Induced Endometrial Inflammatory Response by Targeting TNF Receptor-Associated Factor 6 (TRAF6). J. Inflamm. Res. 2022, 15, 807. [Google Scholar] [CrossRef]
  62. Yeh, W.-C.; Shahinian, A.; Speiser, D.; Kraunus, J.; Billia, F.; Wakeham, A.; De La Pompa, J.L.; Ferrick, D.; Hum, B.; Iscove, N. Early lethality, functional NF-κB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity 1997, 7, 715–725. [Google Scholar] [CrossRef]
  63. Rothe, M.; Wong, S.C.; Henzel, W.J.; Goeddel, D.V. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 1994, 78, 681–692. [Google Scholar] [CrossRef]
  64. Wang, Z.; Li, Y.-f.; Han, X.-y.; Sun, Y.-s.; Zhang, L.-x.; Liu, W.; Liu, X.-x.; Li, W.; Liu, Y.-y. Kidney protection effect of ginsenoside re and its underlying mechanisms on cisplatin-induced kidney injury. Cell. Physiol. Biochem. 2018, 48, 2219–2229. [Google Scholar] [CrossRef]
  65. Wang, W.; Sun, H.; Che, Y.; Jiang, X. Rasfonin promotes autophagy and apoptosis via upregulation of reactive oxygen species (ROS)/JNK pathway. Mycology 2016, 7, 64–73. [Google Scholar] [CrossRef] [Green Version]
  66. Park, J.G.; Aziz, N.; Cho, J.Y. MKK7, the essential regulator of JNK signaling involved in cancer cell survival: A newly emerging anticancer therapeutic target. Ther. Adv. Med. Oncol. 2019, 11, 1758835919875574. [Google Scholar] [CrossRef] [PubMed]
  67. Mathien, S.; Tesnière, C.; Meloche, S. Regulation of Mitogen-Activated Protein Kinase Signaling Pathways by the Ubiquitin-Proteasome System and Its Pharmacological Potential. Pharmacol. Rev. 2021, 73, 1434–1467. [Google Scholar] [CrossRef] [PubMed]
  68. Cederbaum, A.I.; Lu, Y.; Wang, X.; Wu, D. Synergistic toxic interactions between CYP2E1, LPS/TNFα, and JNK/p38 MAP kinase and their implications in alcohol-induced liver injury. Biol. Basis Alcohol-Induc. Cancer 2015, 815, 145–172. [Google Scholar]
Metabolites 12 00792 g001 550
Figure 1. Compound–common targets of the identified compounds of J. grandiflorum flower (JGF). Pink rectangle shapes represent the identified compounds from JGF; blue circles indicate common targets of identified compounds. Edges indicate interactions between identified compounds and common targets.
Figure 1. Compound–common targets of the identified compounds of J. grandiflorum flower (JGF). Pink rectangle shapes represent the identified compounds from JGF; blue circles indicate common targets of identified compounds. Edges indicate interactions between identified compounds and common targets.
Metabolites 12 00792 g001
Metabolites 12 00792 g002 550
Figure 2. PPI of the hit targets of the identified compounds of J. grandiflorum flower (JGF): results represented in four clusters obtained from the STRING online database; dotted lines represent interactions between clusters, solid lines represent interactions between proteins.
Figure 2. PPI of the hit targets of the identified compounds of J. grandiflorum flower (JGF): results represented in four clusters obtained from the STRING online database; dotted lines represent interactions between clusters, solid lines represent interactions between proteins.
Metabolites 12 00792 g002
Metabolites 12 00792 g003 550
Figure 3. Targets—urogenital diseases network analysis. Blue circles represent targets, and pink ones represent renal disease types.
Figure 3. Targets—urogenital diseases network analysis. Blue circles represent targets, and pink ones represent renal disease types.
Metabolites 12 00792 g003
Metabolites 12 00792 g004 550
Figure 4. Targets—acute renal failure network analysis. Green circles represent the target, and orange rectangles represent types of renal failure.
Figure 4. Targets—acute renal failure network analysis. Green circles represent the target, and orange rectangles represent types of renal failure.
Metabolites 12 00792 g004
Metabolites 12 00792 g005 550
Figure 5. The total merged networking of J. grandiflorum identified compounds, targeted genes, and targeted renal diseases in code forms. The pink oval shapes represent renal diseases, pink rectangles represent identified compounds (PCIDs), blue circles represent target genes (gene IDs), and the blue rectangle represents JGF.
Figure 5. The total merged networking of J. grandiflorum identified compounds, targeted genes, and targeted renal diseases in code forms. The pink oval shapes represent renal diseases, pink rectangles represent identified compounds (PCIDs), blue circles represent target genes (gene IDs), and the blue rectangle represents JGF.
Metabolites 12 00792 g005
Metabolites 12 00792 g006 550
Figure 6. The top pathways enriched to the target hits of JGF involved in the acute renal failure diseases illustrate the directly involved genes among JGF target hits. Red rectangles are the target genes in each pathway: (A) PI3K-Akt signaling pathway, (B) MAPK signaling pathway.
Figure 6. The top pathways enriched to the target hits of JGF involved in the acute renal failure diseases illustrate the directly involved genes among JGF target hits. Red rectangles are the target genes in each pathway: (A) PI3K-Akt signaling pathway, (B) MAPK signaling pathway.
Metabolites 12 00792 g006
Metabolites 12 00792 g007 550
Figure 7. Gene ontology analysis of all target genes of active compounds of JGF: (A) cellular components, (B) biological processes, (C) molecular functions.
Figure 7. Gene ontology analysis of all target genes of active compounds of JGF: (A) cellular components, (B) biological processes, (C) molecular functions.
Metabolites 12 00792 g007
Metabolites 12 00792 g008 550
Figure 8. Effects of J. grandiflorum (JGF) on body weight, renal BUN, and serum creatinine. *, #, @, $ indicates significant change from control, cisplatin group (CP), J. grandiflorum-treated group (JGF), and cisplatin + J. grandiflorum-treated group (CP + JGF), respectively.
Figure 8. Effects of J. grandiflorum (JGF) on body weight, renal BUN, and serum creatinine. *, #, @, $ indicates significant change from control, cisplatin group (CP), J. grandiflorum-treated group (JGF), and cisplatin + J. grandiflorum-treated group (CP + JGF), respectively.
Metabolites 12 00792 g008
Metabolites 12 00792 g009 550
Figure 9. Effects of J. grandiflorum (JGF) on renal oxidative stress (GSH and MDA). *, #, @, $ indicates significant change from control, cisplatin group (CP), J. grandiflorum-treated group (JGF), and cisplatin + J. grandiflorum-treated group (CP + JGF), respectively, at p < 0.05.
Figure 9. Effects of J. grandiflorum (JGF) on renal oxidative stress (GSH and MDA). *, #, @, $ indicates significant change from control, cisplatin group (CP), J. grandiflorum-treated group (JGF), and cisplatin + J. grandiflorum-treated group (CP + JGF), respectively, at p < 0.05.
Metabolites 12 00792 g009
Metabolites 12 00792 g010 550
Figure 10. Effects of J. grandiflorum (JGF) on the MMK4, MMK7, ICAM-1, IL-6, and TRAF2 gene expression levels. *, #, @, $ indicates significant change from control, cisplatin group (CP), J. grandiflorum-treated group (JGF), and cisplatin + J. grandiflorum-treated group (CP + JGF), respectively, p < 0.001.
Figure 10. Effects of J. grandiflorum (JGF) on the MMK4, MMK7, ICAM-1, IL-6, and TRAF2 gene expression levels. *, #, @, $ indicates significant change from control, cisplatin group (CP), J. grandiflorum-treated group (JGF), and cisplatin + J. grandiflorum-treated group (CP + JGF), respectively, p < 0.001.
Metabolites 12 00792 g010
Metabolites 12 00792 g011 550
Figure 11. Effects of JGF on histopathological examination of rat kidney. (A) The section in the cortex from the normal group consists of glomeruli, proximal convoluted tubules, and distal convoluted tubules. (B) The section in the cortex of a rat that received cisplatin shows severe effects on the renal tubules, with signs of tubular cell lining vacuolation and intratubular cast deposition (arrowheads). (C) A section in the cortex of a rat that received JGF, consisting of glomeruli, proximal convoluted tubules, and distal convoluted tubules. (D) The section in the cortex of a rat that received cisplatin + JGF shows almost normal renal glomeruli and tubules, apart from minimal tubular cell lining vacuolations ((H,E) section × 200 bar = 50 µm).
Figure 11. Effects of JGF on histopathological examination of rat kidney. (A) The section in the cortex from the normal group consists of glomeruli, proximal convoluted tubules, and distal convoluted tubules. (B) The section in the cortex of a rat that received cisplatin shows severe effects on the renal tubules, with signs of tubular cell lining vacuolation and intratubular cast deposition (arrowheads). (C) A section in the cortex of a rat that received JGF, consisting of glomeruli, proximal convoluted tubules, and distal convoluted tubules. (D) The section in the cortex of a rat that received cisplatin + JGF shows almost normal renal glomeruli and tubules, apart from minimal tubular cell lining vacuolations ((H,E) section × 200 bar = 50 µm).
Metabolites 12 00792 g011
Table
Table 1. Phytochemical profiling of J. grandiflorum flower (JGF) in negative mode HPLC-PDA-MS/MS.
Table 1. Phytochemical profiling of J. grandiflorum flower (JGF) in negative mode HPLC-PDA-MS/MS.
NoCompoundRTm/zFragmentsOntology
11-Caffeoylquinic acid17.04353.16191, 179Phenolic acid
2Verbascoside25.02623.59461, 161Phenylpropanoid
3Elenolic acid glucopyranoside27.38403.95241, 179Secoiridoids
4Quercetin-3-O-pentosyl (1–2) acetylpentoside27.99607.11433, 301Flavonoid glycosides
5Quercetin 3-rutinoside30.09609.22463, 301Flavonol glycosides
6Quercetin-3-O-sophoroside33.14624.94463, 301Flavonol glycosides
7Myricetin-3-O- glucopyranoside34.10479.08317, 195Flavonoid-3-glycosides
8Eriodictyol-7-O-neohesperidoside34.14595.23289, 163Flavonoid-7-glycosides
9Kaempferol 3,7 Di-glucoside35.13609.32285, 179Flavonoid glycosides
1010-hydroxyoleuropein36.21555.08539, 249Secoiridoids
11Vicenin-237.04593.28503, 353Flavonoid 8-C-glycosides
12Oleuropein glucoside38.75701.31529, 223Secoiridoids
13Kaempferol-7-O-glucoside40.46447.34285, 177Flavonol glycosides
14Isorhamnetin-3-O- glucoside41.84477.03315, 193Flavonoid 8-C-glycosides
15Isoquercitrin43.41463.08301, 179Flavonoid 8-C-glycosides
16Multifloroside44.83677.31661, 539Secoiridoids
17Oleuropein46.46539.17377, 233Secoiridoids
18Kaempferitrin47.44577.31285, 179Flavonoid 8-C-glycosides
19Reynoutrin49.18433.10301Flavonoid glycosides
20Quercetin 3-(6″-acetylglucoside)51.08505.02301, 271Flavonol glycosides
21Myricetin 3-xyloside56.41449.05317, 179Flavonoid-3-glycosides
22Laricitrin 3-O-glucoside58.48493.10331, 151Flavonoid glycosides
23Myricitrin59.39463.28317, 179Flavonoid-3-O-glycosides
24Kaempferol61.25285.30269, 241Flavonoid glycosides
25Quercetin61.62301.17245, 179Flavonoid
265-O-Methyllicoricidin66.82483.61203, 177Flavan
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Alqahtani, M.J.; Mostafa, S.A.; Hussein, I.A.; Elhawary, S.; Mokhtar, F.A.; Albogami, S.; Tomczyk, M.; Batiha, G.E.-S.; Negm, W.A. Metabolic Profiling of Jasminum grandiflorum L. Flowers and Protective Role against Cisplatin-Induced Nephrotoxicity: Network Pharmacology and In Vivo Validation. Metabolites 2022, 12, 792. https://doi.org/10.3390/metabo12090792

AMA Style

Alqahtani MJ, Mostafa SA, Hussein IA, Elhawary S, Mokhtar FA, Albogami S, Tomczyk M, Batiha GE-S, Negm WA. Metabolic Profiling of Jasminum grandiflorum L. Flowers and Protective Role against Cisplatin-Induced Nephrotoxicity: Network Pharmacology and In Vivo Validation. Metabolites. 2022; 12(9):792. https://doi.org/10.3390/metabo12090792

Chicago/Turabian Style

Alqahtani, Moneerah J., Sally A. Mostafa, Ismail A. Hussein, Seham Elhawary, Fatma A. Mokhtar, Sarah Albogami, Michał Tomczyk, Gaber El-Saber Batiha, and Walaa A. Negm. 2022. "Metabolic Profiling of Jasminum grandiflorum L. Flowers and Protective Role against Cisplatin-Induced Nephrotoxicity: Network Pharmacology and In Vivo Validation" Metabolites 12, no. 9: 792. https://doi.org/10.3390/metabo12090792

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop